Eli Lilly and Company has announced that the Egyptian Drug Authority has granted approval for the insulin glargine injection produced by EVA Pharma as part of a collaboration with Eli Lilly (LLY). This partnership is an element of Lilly's 30x30 initiative, which aims to enhance healthcare access for 30 million individuals in resource-limited areas each year by 2030. This approval represents the first regulatory endorsement of EVA Pharma's insulin products, stemming from their partnership with Lilly. Lilly has been supplying EVA Pharma with the active pharmaceutical ingredient needed for insulin production.
In addition, EVA Pharma has submitted an application for local regulatory approval of its human insulin injection. In conjunction with Lilly, EVA Pharma is working with the World Health Organization to obtain WHO pre-qualification for the locally manufactured human insulin injection.
The material has been provided by InstaForex Company - www.instaforex.com
In addition, EVA Pharma has submitted an application for local regulatory approval of its human insulin injection. In conjunction with Lilly, EVA Pharma is working with the World Health Organization to obtain WHO pre-qualification for the locally manufactured human insulin injection.
The material has been provided by InstaForex Company - www.instaforex.com